Homer Adams

1.4k total citations
25 papers, 713 citations indexed

About

Homer Adams is a scholar working on Oncology, Hematology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Homer Adams has authored 25 papers receiving a total of 713 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 14 papers in Hematology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Homer Adams's work include Multiple Myeloma Research and Treatments (12 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Homer Adams is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), CAR-T cell therapy research (10 papers) and Monoclonal and Polyclonal Antibodies Research (9 papers). Homer Adams collaborates with scholars based in United States, Netherlands and Denmark. Homer Adams's co-authors include Niels W.C.J. van de Donk, Amy Axel, A. Kate Sasser, Sagar Lonial, Tineke Casneuf, Henk M. Lokhorst, Tuna Mutis, Christopher Chiu, Ian P. Whitehead and Torben Plesner and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Homer Adams

25 papers receiving 699 citations

Peers

Homer Adams
Kenneth Wen United States
Lijie Xing China
Paola Storti Italy
Michael S. van der Veer Netherlands
Michael R. Burgess United States
Daniel W. Sherbenou United States
Grégory Ehx Belgium
Christina Krupka Germany
Jenny Craigen United Kingdom
Kenneth Wen United States
Homer Adams
Citations per year, relative to Homer Adams Homer Adams (= 1×) peers Kenneth Wen

Countries citing papers authored by Homer Adams

Since Specialization
Citations

This map shows the geographic impact of Homer Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Homer Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Homer Adams more than expected).

Fields of papers citing papers by Homer Adams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Homer Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Homer Adams. The network helps show where Homer Adams may publish in the future.

Co-authorship network of co-authors of Homer Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Homer Adams. A scholar is included among the top collaborators of Homer Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Homer Adams. Homer Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bajaj, Gaurav, Oleg Demin, Homer Adams, et al.. (2025). Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data. Clinical Pharmacology & Therapeutics. 118(2). 418–427. 1 indexed citations
2.
Muik, Alexander, Friederike Gieseke, Tahamtan Ahmadi, et al.. (2023). Abstract 3281: GEN1042 (DuoBody-CD40x4-1BB)®in combination with PD-1 blockade reverses T-cell exhaustion in vitro. Cancer Research. 83(7_Supplement). 3281–3281. 1 indexed citations
3.
Martens, Anne W. J., Renate de Boer, An Ngo‐Huang, et al.. (2022). Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. Cancer Research Communications. 2(5). 330–341. 9 indexed citations
4.
Fernandez, Nicolas, Deepak Perumal, Adeeb Rahman, et al.. (2022). High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments. Clinical Lymphoma Myeloma & Leukemia. 22(11). 853–862. 5 indexed citations
5.
Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2022). Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma. Targeted Oncology. 17(4). 433–439. 10 indexed citations
6.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Mark van Duin, et al.. (2021). Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances. 5(8). 2196–2215. 117 indexed citations
7.
Frerichs, Kristine A., Marloes E.C. Broekmans, Berris van Kessel, et al.. (2020). Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab. Clinical Cancer Research. 26(9). 2203–2215. 68 indexed citations
8.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Amy P. Wong, et al.. (2020). Mechanisms of Resistance and Determinants of Response of the GPRC5D-Targeting T-Cell Redirecting Bispecific Antibody JNJ-7564 in Multiple Myeloma. Blood. 136(Supplement 1). 8–9. 7 indexed citations
9.
Girgis, Suzette, Shun Xin Wang Lin, Kodandaram Pillarisetti, et al.. (2020). Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients. Blood. 136(Supplement 1). 35–35. 1 indexed citations
10.
Verkleij, Christie P.M., Marloes E.C. Broekmans, Mark van Duin, et al.. (2019). Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(10). e122–e123. 5 indexed citations
11.
Cole, Suzanne, Alice M. Walsh, Xuefeng Yin, et al.. (2018). Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Research & Therapy. 20(1). 85–85. 85 indexed citations
12.
Casneuf, Tineke, Homer Adams, Andrew C. Lysaght, et al.. (2017). Proteomic Profiling Reveals Targetable Pathways in MGUS (SLAMF6, TNFRSF8, TIMP1, TRL2) That May Contribute to Disease Progression. Blood. 130. 3805–3805. 1 indexed citations
13.
Casneuf, Tineke, Xu Steven Xu, Homer Adams, et al.. (2017). Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Advances. 1(23). 2105–2114. 160 indexed citations
14.
15.
Lamble, Adam J., Yoko Kosaka, Fei Huang, et al.. (2016). Mass Cytometry As a Modality to Identify Candidates for Immune Checkpoint Inhibitor Therapy within Acute Myeloid Leukemia. Blood. 128(22). 2829–2829. 3 indexed citations
16.
Lamble, Adam J., Yoko Kosaka, Fei Huang, et al.. (2016). Enhanced VISTA Expression in a Subset of Patients with Acute Myeloid Leukemia. Blood. 128(22). 4056–4056. 6 indexed citations
17.
Pannucci, Nicole L., Emily K. Thomas, Tianxiang Hu, et al.. (2013). Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity. Blood Cancer Journal. 3(8). e135–e135. 3 indexed citations
18.
Lewis, Michael T., John D. Landua, Homer Adams, & Daniel Medina. (2012). A Mystery Wrapped in an Enigma: Matrigel Enhancement of Mammary Cell Growth and Morphogenesis. Journal of Mammary Gland Biology and Neoplasia. 17(2). 99–101. 8 indexed citations
19.
Adams, Homer, et al.. (2010). Regulation of breast cancer cell motility by T-cell lymphoma invasion and metastasis-inducing protein. Breast Cancer Research. 12(5). R69–R69. 22 indexed citations
20.
Adams, Homer, et al.. (2009). The Rho-specific Guanine Nucleotide Exchange Factor Dbs Regulates Breast Cancer Cell Migration. Journal of Biological Chemistry. 284(23). 15771–15780. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth Wen Breakdown of academic impact, for papers by Lijie Xing Breakdown of academic impact, for papers by Paola Storti Breakdown of academic impact, for papers by Michael S. van der Veer Breakdown of academic impact, for papers by Michael R. Burgess Breakdown of academic impact, for papers by Daniel W. Sherbenou Breakdown of academic impact, for papers by Grégory Ehx Breakdown of academic impact, for papers by Christina Krupka Breakdown of academic impact, for papers by Jenny Craigen
Rankless by CCL
2026